Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
465 results about "Fc fusion" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fc fusion proteins of human erythropoietin with increased biological activities
InactiveUS6900292B2Improve biological activityExtended serumPeptide/protein ingredientsAntibody mimetics/scaffoldsSide effectHalf-life
Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such HuEPO-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Owner:LONGBIO PHARM (SUZHOU) CO LTD
Fc fusion proteins of human erythropoietin with increased biological activities
InactiveUS20050124045A1Improve biological activityExtended serumPeptide/protein ingredientsAntibody mimetics/scaffoldsSide effectHalf-life
Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such HuEPO-L-vFc fusion proteins exhibit extended serum half-life and increased biological activities, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
Owner:SUN LEE HWEI K +2
Fc fusion
InactiveUS20060083747A1Extended half-lifeHigh affinityAntibacterial agentsNervous disorderEpitopeIn vivo
The present invention relates to a simple method for generating antibody-based structures suitable for in vivo use. In particular, the invention relates to a method for the generation of antibody-based structures suitable for in vivo use comprising the steps of: (a) selecting an antibody single variable domain having an epitope binding specificity; and (b) attaching the single domain of step (a) to an effector group. Uses of molecules generated using the method of the Invention are also described.
Owner:DORMANTIS LTD
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
A method for enhancing a binding activity of an antibody composition to Fcgamma receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcgamma receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.
Owner:KYOWA HAKKO KIRIN CO LTD
Antibodies comprising chimeric constant domains
ActiveUS20140243504A1Reduced effector functionAnimal cellsHybrid immunoglobulinsFc(alpha) receptorFc receptor
Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
Owner:REGENERON PHARM INC
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
InactiveUS7067110B1Improving immunogenicityStrengthIn-vivo radioactive preparationsAntibody mimetics/scaffoldsPeptide antigenFc(alpha) receptor
Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells, thereby targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants, for example, an Fc-adjuvant fusion protein, for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected antigen.
Owner:MERCK PATENT GMBH
Antibodies and Fc fusion proteins with altered immunogenicity
InactiveUS20060275282A1Low affinityMaintain activityAntibody mimetics/scaffoldsImmunoglobulins against animals/humansVaccine ImmunogenicityAntibody
Variant antibodies and Fc fusion proteins with reduced immunogenicity are described. In particular, the variants of antibodies and Fc fusion proteins have reduced ability to bind one or more human class II MHC molecules are described.
Owner:XENCOR INC
Antibodies comprising chimeric constant domains
ActiveUS9359437B2Hybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsFc(alpha) receptorFc receptor
Owner:REGENERON PHARM INC
Optimized Fc variants and methods for their generation
InactiveUS20070003546A1Great potentialImmunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibodyChemistry
Owner:XENCOR
Insulin-Fc fusion protein
ActiveCN103509118AImprove pharmacokinetic performanceProlong half-life in vivoPeptide/protein ingredientsMetabolism disorderHalf-lifeMedicine
The invention belongs to a biological technology field, more concretely discloses an insulin-Fc fusion protein, a preparation method and applications thereof. The insulin-Fc fusion protein provided by the invention has a long half life, can reduce interval time of insulin usage, and can reduce medicine use pain.
Owner:SHANGHAI SINOMAB BIOTECHNOLOGY CO LTD
Antibody-based therapeutics with enhanced ADCC activity
Owner:GENZYME CORP
Antibody-based therapeutics with enhanced ADCC activity
Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.
Owner:GENZYME CORP
Fibroblast growth factor-21-Fc fusion proteins
ActiveUS9006400B2Easy to controlImproved profilePeptide/protein ingredientsAntibody mimetics/scaffoldsProtein CFibroblast growth factor receptor 1
Owner:NOVARTIS AG
Immunomodulatory compositions and uses therefor
The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-δ, and RPTP-σ expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein.
Owner:VIRAL LOGIC SYST TECH CORP
Expression and export of interferon-alpha proteins as Fc fusion proteins
InactiveUS20050042729A1Promote productionEfficient productionPeptide/protein ingredientsAntibody mimetics/scaffoldsRNA SequenceHepatitis
Disclosed are nucleic acid sequences, for example, DNA or RNA sequences, which encode an immunoglobulin Fc-Interferon-alpha fusion protein. The nucleic acid sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of immunoglobulin Fc-Interferon-alpha fusion proteins that can be produced by expression of such nucleic acid sequences. Also disclosed are methods of using such nucleic acid sequences and / or fusion proteins for treating conditions, for example, hepatitis, which are alleviated by the administration of interferon-alpha.
Owner:EMD LEXIGEN RES CENT CORP
Interfusion protein of human interleukin 15 and Fe
ActiveCN1760209APeptide/protein ingredientsAntibody ingredientsWhite blood cellImmunoglobulin Fc Fragments
A human interleukin 15-Fc fusion protein composed of interleukin 15 and the Fc fragment of human immunoglobulin, which are linked via joining peptide, the nucleic acid ofr coding it, the expression carrier containing said nucleic acid, its composite medicine for preventing and treating microbial infection and its preparing process are disclosed.
Owner:上海海欣生物技术有限公司
Production of fc-fusion polypeptides in eukaryotic algae
InactiveUS20110151515A1Increase serum stabilityEfficient separation and purificationUnicellular algaeVaccinesHeterologousProtein regulation
Methods and compositions are disclosed to engineer plastids comprising heterologous genes encoding immuno-activating domains fused to an extracellular domain (ECD) of a receptor or surface glycoprotein, a growth factor or an enzyme and produced within a subcellular organelle, such as a chloroplast. The immuno-activating domains may include those regions of a protein capable of modulating the interaction between immune effector cells via proteins containing stereoselective binding domains and specific ligands, such as the Fc regions of antibodies. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain fusion proteins as soluble bioactive therapeutic agents.
Owner:SAPPHIRE ENERGY
Treatment of CD47+ Disease Cells with SIRP Alpha-FC Fusions
ActiveUS20150329616A1Good effectHigh affinityAnimal cellsImmunoglobulin superfamilyCancer cellErythrocyte binding
CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRPα / CD47 axis. The agent is a human SIRPα fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRPα, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRPα. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
Owner:PFIZER INC
Optimized Fc variants and methods for their generation
ActiveUS20070160597A1Immunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesVirology
Owner:XENCOR INC
Engineered Antibody Constant Regions for Site-Specific Conjugation and Methods and Uses Therefor
The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, Cγ, Cκ, and Cλ) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.
Owner:PFIZER INC
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
ActiveUS7625564B2Enhanced erythropoietic bioactivityExtended half-lifePeptide/protein ingredientsAntibody mimetics/scaffoldsHalf-lifeRed blood cell
Owner:NOVAGEN HLDG CORP
Methods of using CD44 fusion proteins to treat cancer
Pharmaceutical compositions and methods for treating cancer using CD44 antagonists are disclosed. In certain aspects, these pharmaceutical compositions and methods include treating a mammal having a cancer, such as glioma, colon cancer, breast cancer, prostate cancer, ovarian cancer, lung cancer, renal cell carcinoma, gastric cancer, esophageal cancer, head cancer, neck cancer, pancreatic cancer, or melanoma, with a CD44 fusion protein. These CD44 fusion proteins include CD44-Fc fusions and can be used to detect hyaluronan.
Owner:CENT HOSPITALER UNIV VAUDOIS UNIV OF LAUSANNE +1
CD52 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
Owner:XENCOR INC
Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc)
ActiveCN103539860AImprove biological activitySmall toxicityPeptide/protein ingredientsAntibody mimetics/scaffoldsRecombinant human follicle stimulating hormoneSide effect
The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The recombinant hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G)2 Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and smaller side effects than existing hFSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs for treating and / or preventing infertility.
Owner:UNICOHEALTH CO LTD
Optimized Fc variants and methods for their generation
InactiveUS20070053901A1Immunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibodyChemistry
Owner:XENCOR INC
GLP/1/EXENDIN 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
ActiveUS20090181912A1Increase beta-cell proliferationReduces beta-cell apoptosisOrganic active ingredientsPeptide/protein ingredientsPeptideProtein C
The invention is a method and composition for the prevention and treatment of type I and type II diabetes in a subject. The composition comprises an IgG-Fc fusion protein where the fusion protein comprises GLP-1, mutant GLP-1, or exendin-4.
Owner:GUANGZHOU INNOGEN PHARMA GRP CO LTD
Enhancing Anti-cancer activity of immunomodulatory fc fusion proteins
InactiveUS20150322119A1Enhance immune responseImprove bindingAntibody mimetics/scaffoldsAntibody ingredientsFc(alpha) receptorAbnormal tissue growth
The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method which has an enhanced ability to potentiate an endogenous immune response against cells of a cancer or an infectious agent in a subject. The disclosure further provides a method for treating a subject which comprises administering to the subject a therapeutically effective amount of an Fc fusion protein, wherein the Fc region of the Fc fusion protein has been selected, designed or modified so as to increase the binding of said Fc region to an activating FcR.
Owner:BRISTOL MYERS SQUIBB CO
Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
ActiveUS20120116057A1Improve homogeneityReduce level of aggregationAnimal cellsBacteriaAmino acid substitutionAmino acid
The present invention relates to methods of increasing stability and reducing aggregation in compositions comprising antibody Fc molecules and to composition comprising such molecules. Certain amino acid substitutions in the CH3 domain result in increased stability and reduced aggregation of compositions containing polypeptides comprising a CH3 domain, e.g., an antibody or Fc-fusion protein.
Owner:AMGEN INC
Human interleukin-2 (IL-2)/Fc fusion protein
ActiveCN102174111AEnhance humoral immune responseImprove immunityPeptide/protein ingredientsDigestive systemRegulatory T cellHalf-life
The invention provides human interleukin interleukin-2 (IL-2) / Fc fusion protein. The human IL-2 of the fusion protein comprises all sequences of a human IL-2 extracellular region; the Fc fragments comprise a hinge region, a CH2 region and a CH3 region; the human IL-2 / Fc sequences are fused directly or through a connection sequence; and the Fc fragments are human or animal IgG, IgM, IgD and IgA orsubtypes thereof. The ADCC and CDC effective factor action can be eliminated, and in addition, the human IL-2 / Fc fusion protein has the compatibility with a recombinant IL-2 receptor so that the half-life period is obviously prolonged and also has all the biological activity of the IL-2 receptor. The IL-2 / Fc obviously improves the humoral immune response stimulated by the hepatitis B vaccine and the immunity of the CD8+T cells targeted to the hepatitis B vaccine. Moreover, the balance immune (suppression) of the effective T cells and the regulatory t cells can be adjusted under the action of the cyclosporine A so that the pancreatic islet transplantation immune tolerance is induced.
Owner:上海百英生物科技股份有限公司
Cns-targeted conjugates having modified fc regions and methods of use thereof
InactiveUS20150093399A1Reduce transportationAltering distribution of the conjugatePeptide/protein ingredientsImmunoglobulinsNeuropathologyAntibody
Provided are central nervous system (CNS)-targeted antibody or therapeutic Fc-fusion polypeptide conjugates having modified Fc regions, and related methods of use thereof, for instance, to facilitate delivery of therapeutic and / or diagnostic polypeptides across the blood-brain barrier (BBB), and thereby treat and / or diagnose conditions associated with the CNS, including cancer, pain, and various neuropathologies, such as neuroinflammatory, auto-immune, and / or neurodegenerative disorders.
Owner:BIOASIS TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com